Ditchcarbon
  • Customers
  1. Organizations
  2. Glaxosmithkline
Public Profile
Pharmaceutical Preparation Manufacturing
GB
updated 9 days ago

Glaxosmithkline

Company website

GlaxoSmithKline plc (GSK), a leading global healthcare company headquartered in Great Britain, has been at the forefront of pharmaceutical innovation since its founding in 2000, following the merger of Glaxo Wellcome and SmithKline Beecham. With a strong presence in Europe, North America, and emerging markets, GSK operates primarily in the pharmaceutical, vaccine, and consumer healthcare sectors. The company is renowned for its diverse portfolio, which includes groundbreaking medicines, vaccines, and consumer health products that address a wide range of health needs. GSK's commitment to research and development has led to significant advancements in areas such as respiratory diseases, HIV, and immunology. As a key player in the global healthcare landscape, GSK continues to achieve notable milestones, reinforcing its position as a trusted provider of innovative health solutions.

DitchCarbon Score

How does Glaxosmithkline's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

100

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

28

Industry Benchmark

Glaxosmithkline's score of 100 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.

100%

Let us know if this data was useful to you

Glaxosmithkline's reported carbon emissions

In 2024, GlaxoSmithKline (GSK) reported total carbon emissions of approximately 521,000,000 kg CO2e for Scope 1 and 44,000,000 kg CO2e for Scope 2 globally, resulting in a combined total of about 565,000,000 kg CO2e for both scopes. In the UK, GSK's Scope 1 and 2 emissions amounted to approximately 92,000,000 kg CO2e. GSK has set ambitious climate commitments, aiming for net zero emissions across all operations (Scope 1 and 2) by 2030. They achieved a 15% reduction in Scope 1 and 2 emissions from 2020 to 2021. Furthermore, GSK has committed to a long-term target of net zero emissions across their full value chain by 2045, with a goal to reduce absolute emissions by at least 90% from a 2020 baseline across all scopes. The company has also established near-term targets, including a 34% reduction in absolute Scope 1 and 2 emissions by 2025 from a 2017 baseline, and a 16% reduction in absolute Scope 3 emissions by 2030 from the same baseline. GSK's initiatives are aligned with the Science Based Targets initiative (SBTi) and reflect their commitment to sustainable practices within the pharmaceutical industry.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

20102011201220142015201620172018201920202021202220232024
Scope 1
430,000
000,000
000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
Scope 2
-
-
-
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
00,000,000
00,000,000
00,000,000
Scope 3
-
-
-
00,000,000,000
00,000,000,000
00,000,000,000
00,000,000,000
00,000,000,000
-
0,000,000,000
0,000,000,000
0,000,000,000
0,000,000,000
-

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Glaxosmithkline's primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Glaxosmithkline is in GB, which has a low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Glaxosmithkline is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

Haleon Pakistan Limited

PK
•
Pharmaceutical Preparation Manufacturing
Updated 27 days ago

MERCK Kommanditgesellschaft auf Aktien

DE
•
Pharmaceutical Preparation Manufacturing
Updated 4 days ago

Pfizer

US
•
Pharmaceutical Preparation Manufacturing
Updated 17 minutes ago

Regeneron

US
•
Pharmaceutical Preparation Manufacturing
Updated 4 days ago

Lundbeck

DK
•
Pharmaceutical Preparation Manufacturing
Updated 4 days ago

Bristol-Myers Squibb

US
•
Pharmaceutical Preparation Manufacturing
Updated 4 days ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v250821.7
enquiries@ditchcarbon.com+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
Verified byUL Verified
Partnered withCDP
ProductPortalDataDocumentationIntegrationsChangelogPricing
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesMethodologyBlogFAQOrganizationsIndustriesSBTI APITrust Centre
AboutTeamCareersLicense AgreementPrivacy